United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy. bySrinathFebruary 12, 2026